Holen Sie sich die Stockscreener-App
1.8502
3.63%
0.0602
Schlusskurs vom Vortag:
$1.79
Offen:
$1.82
24-Stunden-Volumen:
108.94K
Relative Volume:
0.89
Marktkapitalisierung:
$27.68M
Einnahmen:
$486.00K
Nettoeinkommen (Verlust:
$-28.43M
KGV:
-0.6564
EPS:
-2.8189
Netto-Cashflow:
$-26.75M
1W Leistung:
+1.92%
1M Leistung:
+7.85%
6M Leistung:
-22.71%
1J Leistung:
-21.06%
1-Tages-Spanne:
$1.77
$1.89
1-Wochen-Bereich:
$1.75
$1.89
52-Wochen-Spanne:
$1.44
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Firmenname
Vyne Therapeutics Inc
Sektor
Branche
Telefon
800-775-7936
Adresse
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Vergleichen Sie VYNE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
1.85 | 27.68M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.05 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.76 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.84 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.78 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.34 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Eingeleitet | BTIG Research | Buy |
| 2021-12-06 | Fortgesetzt | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Aktie (VYNE) Neueste Nachrichten
Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN
Invesco Canada announces cash distributions for its ETFs - The Globe and Mail
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan
VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World
VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com
VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz
VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World
HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times
Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan
VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq
Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times
Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan
VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia
Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance
VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World
Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga
VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo - Marketscreener.com
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluat - WICZ
VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 - StockTitan
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - Yahoo Finance
VYNE stock soars to 52-week high, touches $3.43 By Investing.com - Investing.com South Africa
VYNE stock soars to 52-week high, touches $3.43 - Investing.com
VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202 - Defense World
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data - Yahoo Finance
VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
VYNE Therapeutics Reports Positive Phase 1a MAD Data for BD2-Selective BET Inhibitor VYN202 - Dermatology Times
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - The Manila Times
Finanzdaten der Vyne Therapeutics Inc-Aktie (VYNE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
2.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):